Retrospective analysis of bevacizumab in combination with fotemustine in chinese patients with recurrent glioblastoma multiforme

BioMed Research International
Zhiguang LiuXiaorong Zhuang

Abstract

The aim of this study was to assess the activity and safety of bevacizumab (BEV) and fotemustine (FTM) for the treatment of recurrent glioblastoma multiforme (GBM) patients and explore the potential prognostic parameters on survival. This study retrospectively analyzed all patients with GBM who were treated with at least one cycle of BEV and FTM from July 2010 to October 2012. A total of 176 patients with recurrent GBM were enrolled. The response rate and disease control rate were 46.6% and 90.9%, respectively. A 6-month PFS rate of 33.3% (95% CI: 26.5%-40.3%) and a median PFS of 5.0 (95% CI: 2.4-7.5) months were observed. The median OS was 8.0 (95% CI: 6.7-9.2) months. Multivariate analysis showed that risk factors with a significant influence on the PFS of all patients were Karnofsky Performance Status (KPS) (≥70 versus <70, HR = 0.53, 95% CI: 0.39-0.73, and P = 0.01) and MGMT status (methylated versus unmethylated, HR = 0.69, 95% CI: 0.52-0.97, and P = 0.04). The most common treatment-related adverse events were fatigue, proteinuria, hypophonia, hypertension, thrombocytopenia, anemia, and neutropenia. In conclusion, combination of BEV with FTM is well tolerated and may derive some clinical benefits in recurrent GBM patients....Continue Reading

References

Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M F AvrilY Menu
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jul 10, 2007·Acta Neuropathologica·David N LouisPaul Kleihues
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antje WickWolfgang Wick
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James J VredenburghHenry S Friedman
Nov 13, 2007·Neuro-oncology·Graziella FilippiniUNKNOWN Brain Cancer Register of the Fondazione IRCCS (Istituto Ricovero e Cura a Carattere Scientifico) Istituto Neurologico Carlo
Oct 24, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J SadonesB Neyns
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teri N KreislHoward A Fine
Jul 14, 2009·Journal of Neuro-oncology·Marc C Chamberlain, Sandra K Johnston
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Nov 17, 2009·European Journal of Cancer Care·A M StarkH M Mehdorn
Jan 13, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J J C VerhoeffD J Richel
Aug 19, 2010·Neuro-oncology·Sith SathornsumeteeDavid A Reardon
Dec 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Albert LaiTimothy Cloughesy
Mar 23, 2011·International Journal of Cancer. Journal International Du Cancer·Jörg FelsbergUNKNOWN German Glioma Network
Mar 19, 2013·Journal of the Egyptian National Cancer Institute·Niloofar AhmadlooMansour Ansari
Apr 5, 2013·Neuro-oncology·Andrew D NordenPatrick Y Wen
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
May 31, 2014·BioMed Research International·V VaccaroA Pace
Jul 6, 2014·Neurosurgery·Shawn L Hervey-Jumper, Mitchel S Berger

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

SPSS

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.